The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Selecting patients with multiple myeloma for CAR-T therapy
Mahmoud Gaballa, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving indications for CAR-T therapy in multiple myeloma, noting that these treatments are increasingly being used in second and third lines rather than waiting for the fourth line. He highlights that patients with good performance status and sufficient lymphocytes in their blood tend to have better outcomes when CAR-Ts are administered earlier. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
